Scorpion Capital & MiNK Therapeutics

Scorpion Capital: Scorpion Capital issued a report on August 15, 2025, which purportedly caused a disruption in DCCR's launch trajectory and revealed significant issues with MiNK Therapeutics' Phase 3 clinical trial program.

MiNK Therapeutics: MiNK Therapeutics is the defendant in a securities fraud class action lawsuit, accused of making materially false and misleading statements regarding its DCCR clinical trial program, which led to a significant stock price decline.

Scorpion Capital: Scorpion Capital published a critical report on MiNK Therapeutics' drug candidate DCCR, alleging significant concerns regarding its safety, efficacy, and clinical trial data, which led to a decline in MiNK Therapeutics' stock price.

Scorpion Capital: Scorpion Capital, an activist short seller, raised questions about MiNK Therapeutics' disclosures regarding DCCR, contributing to the stock price decline and subsequent lawsuits.